

1 **Title Page**

2 **Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted**  
3 **SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blind,**  
4 **Randomised, Placebo-Controlled Phase 2 Trial**

5  
6 Hsieh Szu-Min, M.D.<sup>1</sup>, Ming-Che Liu, M.D.,<sup>2,3</sup>, Yen-Hsu Chen, M.D.,<sup>4,5</sup>, Wen-Sen Lee,  
7 M.D.<sup>6,7</sup>, Shinn-Jang Hwang, Prof<sup>8</sup>, Shu-Hsing Cheng, M.D.,<sup>9,10</sup>, Wen-Chien Ko, Prof.<sup>11,12</sup>,  
8 Kao-Pin Hwang, M.D.<sup>13</sup>, Ning-Chi Wang, M.D.<sup>14</sup>, Yu-Lin Lee, M.D.<sup>15,16</sup>, Yi-Ling Lin,  
9 Ph.D.<sup>17,18</sup>, Shin-Ru Shih, Ph.D.<sup>19</sup>, Chung Guei Huang, Ph.D.<sup>19,20</sup>, Chun-Che Liao, Ph.D.<sup>17</sup>,  
10 Jian-Jong Liang, Ph.D.<sup>17</sup>, Chih-Shin Chang, PhD.<sup>18</sup>, Charles Chen, adj. Prof.<sup>21,22</sup>, Chia En  
11 Lien, M.D.<sup>21,23</sup>, I-Chen Tai, M.D.\*<sup>21</sup>, Tzou-Yien Lin, Prof.\*<sup>24,25</sup>

- 12  
13 1. Division of Infectious Diseases, Department of Internal Medicine, National Taiwan  
14 University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan  
15 (R.O.C.)  
16 2. Clinical Research Centre, Taipei Medical University Hospital, Taipei, Taiwan (R.O.C.)  
17 3. School of Dental Technology, College of Oral Medicine, Taipei Medical University,  
18 Taipei, Taiwan (R.O.C.)  
19 4. Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical  
20 University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan (R.O.C.)  
21 5. School of Medicine, Graduate Institute of Medicine, Sepsis Research Centre, Centre of  
22 Tropical Medicine and Infectious Diseases, Kaohsiung Medical University, Kaohsiung,  
23 Taiwan (R.O.C.)  
24 6. Division of Infectious Disease, Department of Internal Medicine, Taipei Municipal Wan  
25 Fang Hospital, Taipei Medical University, Taipei, Taiwan (R.O.C.)  
26 7. Department of Internal Medicine, School of Medicine, College of Medicine, Taipei  
27 Medical University, Taipei, Taiwan (R.O.C.)  
28 8. Department of Family Medicine, Taipei Veterans General Hospital and National Yang  
29 Ming Chiao Tung University School of Medicine, Taipei, Taiwan (R.O.C.)  
30 9. Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and  
31 Welfare, Taoyuan, Taiwan (R.O.C.)  
32 10. School of Public Health, Taipei Medical University, Taipei, Taiwan (R.O.C.)  
33 11. Department of Internal Medicine, National Cheng Kung University Hospital, College of  
34 Medicine, National Cheng Kung University, Tainan, Taiwan (R.O.C.)  
35 12. Department of Medicine, College of Medicine, National Cheng Kung University, Tainan,  
36 Taiwan (R.O.C.)  
37 13. School of Medicine, China Medical University Hospital and Children Hospital, China  
38 Medical University, Taichung, Taiwan (R.O.C.)

- 39 14. Tri-Service General Hospital, Taipei, Taiwan (R.O.C.)  
40 15. Department of Internal Medicine, Changhua Christian Hospital, Changhua County,  
41 Taiwan (R.O.C.)  
42 16. Program in Medical Biotechnology, National Chung Hsing University, Taichung City,  
43 Taiwan (R.O.C.)  
44 17. Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (R.O.C.)  
45 18. Biomedical Translation Research Centre, Academia Sinica, Taipei, Taiwan (R.O.C.)  
46 19. Research Centre for Emerging Viral Infections, College of Medicine, Chang Gung  
47 University, Taoyuan City, Taiwan (R.O.C.)  
48 20. Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan  
49 City, Taiwan (R.O.C.)  
50 21. Medigen Vaccine Biologics Corp., Taipei, Taiwan (R.O.C.)  
51 22. College of Science and Technology, Temple University, Philadelphia, PA 19122, U.S.A.  
52 23. Institute of Public Health, College of Medicine, National Yang Ming Chiao Tung  
53 University, Taipei, Taiwan (R.O.C.)  
54 24. Department of Paediatrics, Chang Gung Memorial Hospital, Taoyuan City, Taiwan  
55 (R.O.C.)  
56 25. College of Medicine, Chang Gung University, Taoyuan City, Taiwan (R.O.C.)

57

58 \*Tzou-Yien Lin, Corresponding Author

59 Email: [alinpid@gmail.com](mailto:alinpid@gmail.com)

60 Postal address: Department of Paediatrics, Chang Gung Memorial Hospital.

61 No. 5, Fuxing Street, Guishan District, Taoyuan, 333, Taiwan (R.O.C.)

62 TEL: +886-3-3281200 #8002

63

64 \*I-Chen Tai, Co-corresponding Author

65 Email: [kathytai@medigenvac.com](mailto:kathytai@medigenvac.com)

66 Postal address: Medigen Vaccine Biologics Corp.

67 7<sup>th</sup> Fl., No. 16, Ln. 120, Sec. 1, Neihu Rd., Taipei 114, Taiwan (R.O.C.)

68 TEL: +886-2-77450830 #604

69

70 **Keywords:** Binding antibody units (BAU); Correlates of Protection (CoP); COVID-19  
71 vaccine; International unit (IU); Recombinant protein subunit vaccine; S-2P prefusion  
72 protein;

73

74

75 **Summary**

76 **Background**

77 We have assessed the safety and immunogenicity of the COVID-19 vaccine MVC-COV1901,  
78 a recombinant protein vaccine containing prefusion-stabilized spike protein S-2P adjuvanted  
79 with CpG 1018 and aluminium hydroxide.

80

81 **Methods**

82 This is a phase 2, prospective, randomised, double-blind, placebo-controlled, and  
83 multi-centre study to evaluate the safety, tolerability, and immunogenicity of the  
84 SARS-CoV-2  
85 vaccine candidate MVC-COV1901. The study comprised 3,844 participants of  $\geq 20$  years  
86 who were generally healthy or with stable pre-existing medical conditions. The study  
87 participants were randomly assigned in a 6:1 ratio to receive either MVC-COV1901  
88 containing 15  $\mu\text{g}$  of S-2P protein or placebo containing saline. Participants received two  
89 doses of MVC-COV1901 or placebo, administered 28 days apart via intramuscular injection.  
90 The primary outcomes were to evaluate the safety, tolerability, and immunogenicity of  
91 MVC-COV1901 from Day 1 (the day of first vaccination) to Day 57 (28 days after the  
92 second dose). Immunogenicity of MVC-COV1901 was assessed through geometric mean  
93 titres (GMT) and seroconversion rates (SCR) of neutralising antibody and antigen-specific  
94 immunoglobulin. This clinical trial is registered at ClinicalTrials.gov: NCT04695652.

95

96 **Findings**

97 From the start of this phase 2 trial to the time of interim analysis, no vaccine-related Serious  
98 Adverse Events (SAEs) were recorded. The most common solicited adverse events across all  
99 study participants were pain at the injection site (64%), and malaise/fatigue (35%). Fever was  
100 rarely reported (<1%). For all participants in the MVC-COV1901 group, at 28 days after the  
101 second dose against wild type SARS-CoV-2 virus, the GMT was 662.3 (408 IU/mL), the  
102 GMT ratio was 163.2, and the seroconversion rate was 99.8%.

103

104 **Interpretation**

105 MVC-COV1901 shows good safety profiles and promising immunogenicity responses. The  
106 current data supports MVC-COV1901 to enter phase 3 efficacy trials and could enable  
107 regulatory considerations for Emergency Use Authorisation (EUA).

108

109 **Funding**

110 Medigen Vaccine Biologics Corporation and Taiwan Centres for Disease Control.

111

## 112 **Introduction**

113 In December 2019, the Coronavirus Disease (COVID-19) was first reported in Wuhan, China.  
114 Identified as a SARS related coronavirus, it was named SARS-CoV-2. The disease spread  
115 with such ferocity, the WHO declared a global pandemic on 11 March 2020. Despite the  
116 unprecedented pace of vaccine development, COVID-19 continues to wreak havoc, with over  
117 170 million infections and 3.7 million deaths worldwide as of June 2021.<sup>3</sup> Even though  
118 several vaccines that have obtained Emergency Use Authorisation (EUA), using mRNA  
119 platform or adenovirus vector-based technology, the limitations and global supply of  
120 available vaccines are not enough to end this pandemic. The addition of traditional  
121 recombinant subunit protein vaccines could bolster current vaccination efforts.

122

123 MVC-COV1901 is a recombinant protein subunit vaccine based on the stabilised prefusion  
124 SARS-CoV-2 spike protein S-2P adjuvanted CpG 1018 and aluminium hydroxide.<sup>4,5</sup> The  
125 S-2P protein was developed by McLellan and Graham at the National Institute of Allergy and  
126 Infectious Diseases (NIAID), U.S.A, and the synthetic oligodeoxynucleotide CpG 1018  
127 adjuvant is developed by Dynavax.<sup>4</sup> Using animal models, we have demonstrated a total  
128 protection in hamsters challenged with wild type SARS-COV-2.<sup>6</sup> The result of our phase 1  
129 trial confirmed that MVC-COV1901 is well tolerated and elicits robust immune responses in  
130 both T-cell & B-cell immunity.<sup>7</sup> For this phase 2 trial, we proceeded with the 15 µg spike  
131 S-2P protein MVC-COV1901.

132

133 The purpose of this study is to assess the safety, tolerability, and immunogenicity of the  
134 MVC-COV1901 vaccine against placebo for adult participants who are healthy or with stable  
135 pre-existing medical conditions.

136

## 137 **Methods**

### 138 *Trial design and oversight*

139 This is an ongoing phase 2, prospective, randomised, double-blind, placebo-controlled  
140 (investigator/site staff and participants), multi-centre study. The study sites consisted of ten  
141 medical centres and one regional hospital in Taiwan. We planned to enrol approximately  
142 3,700 adult participants. Participants were to be stratified into two age groups: younger adults  
143 (aged 20-64 years) and older adults (aged 65 years and over). The older adults were to make  
144 up 20% of the participants.

145

146 The trial protocol and informed consent form were approved by Taiwan Food and Drug  
147 Administration (TFDA) and the ethics committees at the conducting sites (Main review  
148 Institutional. Review Board [IRB]: Chang Gung Medical Foundation; sub Review IRBs:  
149 National Taiwan University Hospital; Taipei Veterans General Hospital, Tri-Service General  
150 Hospital, Taipei Medical University Hospital, Taipei Municipal Wanfang Hospital, Taoyuan  
151 General Hospital MOHW, China Medical University Hospital, Changhua Christian Hospital,  
152 National Cheng Kung University Hospital, and Kaoshiung Medical University Hospital).  
153 An Independent Data Monitoring Committee (IDMC) was established to monitor data safety  
154 and trial conduct. The study complies with the protocol and statistical analysis plan. The  
155 protocol is available in the appendix. The trial was conducted in accordance with the  
156 principles of the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines, and is  
157 registered at the ClinicalTrials.gov: NCT 04695652.

158

### 159 *Participants*

160 Participants were male or female adults aged 20 years or over who were healthy or with  
161 stable pre-existing medical conditions. Female participants of child-bearing potential had to  
162 agree to take effective contraception. Those who travelled overseas within 14 days of  
163 screening, or those who planned to travel overseas in six months were excluded from  
164 screening. Participants must not have pre-specified medical conditions, including  
165 immunosuppressive illness, history of autoimmune disease, malignancy with risk to recur,  
166 bleeding disorder, uncontrolled human immunodeficiency virus (HIV), uncontrolled hepatitis  
167 B and C infections, SARS-CoV-1 or 2 virus infections, allergy to any vaccine, or serious  
168 medical conditions that would interfere with the study. A full list of inclusion and exclusion  
169 criteria is available in the protocol. All participants provided signed informed consent.

170

### 171 *Randomisation and masking*

172 Participants were centrally randomised using an interactive web response system (IWRS).  
173 Participants received either MVC-COV1901 or placebo in a 6:1 ratio. The Safety Set of this  
174 interim analysis included all study participants who has received at least one dose of injection.

175 The Per-Protocol Immunogenicity (PPI) Subset planned to include the first 1,090 randomised  
176 participants: 820 participants from the younger adult group and 270 participants from the  
177 older adult group.

178

179 This was a double-blind study in which participants and investigators were blinded to the  
180 study intervention. Since MVC-COV1901 and placebo are visually distinct, each trial site  
181 was assigned an independent study nurse, who was not involved in the preparation,  
182 dispensing, administration, and accountability of the study intervention. To ensure treatment  
183 blindness to all study staff and participants, study-specific training was conducted at every  
184 trial site.

185

### 186 ***Procedures***

187 Each participant received two doses of either MVC-COV1901 or placebo on Visit 2 (Day 1)  
188 and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid. The prefilled  
189 MVC-COV1901 contained 15 µg of CHO cell-derived S-2P protein adjuvanted with CpG  
190 1018 750 µg and aluminium hydroxide 375 µg, as previously reported.<sup>7</sup> The vaccine was  
191 produced at Medigen Vaccine Biologics Corp. facility and complied with the current good  
192 manufacturing practices (cGMP). The placebo was 0.5 mL of saline. The duration of the  
193 study was 209 days (29 days treatment period, 180 days follow-up). Participant data was  
194 collected via six on-site visits and three phone calls.

195

### 196 ***Outcomes***

#### 197 *Safety assessment*

198 The primary safety endpoints were to evaluate the safety and tolerability of all participants  
199 receiving study intervention from Day 1 to Day 57 (28 days after the second dose). Vital  
200 signs were assessed before and after each injection. Participants were observed for at least 30  
201 minutes after each injection to identify any immediate adverse events (AEs). After each  
202 injection, participants had to record solicited local and systemic AEs in their diary cards for  
203 up to seven days. Unsolicited AEs were recorded for 28 days following each injection. All  
204 other AEs, SAEs, adverse events of special interests (AESIs), and vaccine-associated  
205 enhanced disease (VAED) were recorded throughout the study period.

206

#### 207 *Immunogenicity assessment*

208 The primary immunogenicity endpoint was to evaluate neutralising antibody titres on Day 57  
209 in terms of geometric mean titres (GMT), GMT ratio, and seroconversion rate (SCR) in the  
210 PPI Subset. The secondary endpoint was to evaluate the anti-Spike IgG antibody titres on  
211 Day 29 (the day of second dose), Day 43 (14 days after the second dose), and Day 57 in the  
212 PPI Subset.

213

#### 214 *Laboratory methods*

215 Wild type SARS-CoV-2 TCDC#4 strain (hCoV-19/Taiwan/4/2020, GISAID accession ID:  
216 EPI\_ISL\_411927) was titrated to calculate the TCID<sub>50</sub>. Vero E6 cells ( $1.2 \times 10^5$  cells/well)  
217 were seeded in 96-well plates and incubated. The sera underwent a total of ten two-fold  
218 dilutions, starting from a 1:8 dilution to a final dilution of 1:8,192. Diluted sera were mixed  
219 with equal volume of 100 TCID<sub>50</sub>/50  $\mu$ L of virus. The serum-virus mixture was incubated at  
220 37 °C for one hour, and then added to the cell plates containing the Vero E6 cells, followed  
221 by a further incubation at 37 °C, 5% CO<sub>2</sub> incubator for four to five days. The neutralising  
222 titre (NT<sub>50</sub>) was defined as the reciprocal of the highest dilution capable of inhibiting 50% of  
223 the cytopathic effect (CPE). The readouts came from quadruplicated tests that were  
224 calculated using the formula of the Reed-Muench method.

225

226 To facilitate conversion of GMT to WHO's International Unit (IU/mL) or Binding Antibody  
227 Unit (BAU/mL), we purchased WHO international standard reference panels (NIBSC 20/136,  
228 NIBSC 20/268) from National Institute for Biological Standards and Control (NIBSC; Potters  
229 Bar, UK) for comparison.<sup>8,9</sup> (Supplementary Table S1) Our methodology to convert GMT to  
230 IU/mL is as follows: first, a neutralising assay was developed to obtain the GMTs of the  
231 NIBSC sera. The GMTs were verified by three repeated tests. Using the correlation between  
232 the GMTs and its assigned IU/mL of each standardised NIBSC sera, we established an  
233 equation for converting GMT to IU/mL. We applied this equation to convert the GMTs of our  
234 study groups to IU/mL.

235

236 For the conversion of GMT to BAU/mL, the total serum anti-Spike IgG titres were measured  
237 using enzyme-linked immunosorbent assay (ELISA) customized 96-well plates coated with  
238 S-2P antigen, as previously reported.<sup>7</sup> The WHO NIBSC 20/136 was tested with the same  
239 ELISA assay that was used in our study samples. The geometric mean of the anti-Spike IgG  
240 titre for NIBSC 20/163 was 10,960.9, which was calculated from seven repeated tests. Since  
241 NIBSC 20/136 was assigned as 1,000 BAU/mL, a conversion factor of 0.0912  
242 (1,000/10,960.9) was established to predict BAU/mL from anti-Spike IgG titres. The raw data  
243 for the conversion of anti-Spike IgG GMT to BAU/mL is provided in the Supplementary  
244 Table S2.

245

#### 246 *Statistical analysis*

247 The sample size of our trial design meets the minimum safety requirement of 3,000 study  
248 participants for the vaccine group, as recommended by the FDA, and WHO guidance.<sup>10,11</sup> The  
249 immunogenicity data are GMT, GMT ratio, and SCR, which are presented with two-sided

250 95% Confidence Interval (CI). GMT ratio is defined as geometric mean of fold increase of  
251 post-study intervention titres over the baseline titres. SCR is defined as the percentage of  
252 study subjects with  $\geq 4$ -fold increase in titres from the baseline or from half of the lower limit  
253 of detection (LoD) if baseline is undetectable.

254

255 The Safety Set comprises all randomised participants who received at least one dose of study  
256 intervention. The immunogenicity set comprises participants who received planned doses of  
257 study intervention, had valid immunogenicity results on Day 57, and did not have a major  
258 protocol deviation up to Day 57. The PPI Subset was the primary analysis population for the  
259 primary and secondary immunogenicity endpoints in this interim analysis.

260

261 Participants from different study sites were pooled for statistical analysis. Significance tests  
262 (two-tailed,  $\alpha = 0.05$ ) were performed as follows: two-sample t-test or Wilcoxon rank  
263 sum test was used for pairwise comparison of GMT and GMT ratios; Pearson's Chi-square  
264 test or Fisher's exact test (in the case of small cell count or expected count less than five) was  
265 used for calculating significance of SCR results; P-value was rounded to four decimal places,  
266 if applicable. All statistical analyses were performed using SAS® 9.4 or newer versions (SAS  
267 Institute, Cary, NC, USA).

268

#### 269 ***Role of the funding source***

270 Medigen Vaccine Biologics Corp. (MVC) is the sponsor of the study and manufactured the  
271 MVC-COV1901 vaccine in cGMP standard. The sponsor co-designed the trial and  
272 coordinated interactions with the contract Clinical Research Organization (CRO) staff and  
273 regulatory authorities. The CRO took charge of trial operation to meet the required standard  
274 for The International Council for Harmonisation of Technical Requirements for  
275 Pharmaceuticals for Human Use (ICH) and Good Clinical Practice (GCP). The IDMC  
276 oversaw the safety data and gave recommendations to the sponsor. The interim analysis was  
277 performed by the CRO.

278

279 Taiwan Centres for Disease Control (CDC) of the Ministry of Health and Welfare provided  
280 grant funding and guidance for the design of this study, but it had no role in data collection,  
281 data analysis, data interpretation, or drafting of this manuscript.

282



## 283 **Results**

284 From 30 Dec 2020 to 2 Apr 2021, 3,844 participants who received at least one dose of study  
285 intervention (3,295 received MVC-COV1901 and 549 received placebo) were included in the  
286 Safety Set (Figure 1). A total of 1,053 participants fulfilled the definition of the PPI Subset.  
287 The mean age of the Safety Set was 45 years (min 20 years, max 89 years), and the male to  
288 female percentage was 56.3% to 43.7%. Only one participant was non-Asian (white). Most  
289 participants had BMI < 30 kg/m<sup>2</sup> (89.4%), and negative serology tests for HBsAg, anti-HCV  
290 antibody, and HIV antibody at the baseline. A total of 634 (16.5%) participants reported to  
291 have comorbidity, most of whom had higher levels of HbA1c than the normal range (13.4%),  
292 followed by cardiovascular disease (2.6%) and malignancy (1.1%). Demographic  
293 characteristics of the Safety Set are summarised in Table 1.

294

### 295 *Safety*

296 The solicited adverse events are summarised in Figure 2 and Supplementary Tables S3 to S5.  
297 Overall, 2,510 (65.3%) participants reported solicited local AEs after any dose of the study  
298 intervention. The MVC-COV1901 group (2,381 [72.3%]) outnumbered the placebo group  
299 (129 [23.5%]) in reporting solicited local AEs, which were mostly mild (Grade 1) to  
300 moderate (Grade 2) in severity. After any dose of MVC-COV1901, the most common  
301 solicited local AE was pain at the injection site (2,346 [71.2%]), while the most common  
302 solicited systemic AE was malaise/fatigue (1,186 [36.0%]). Fever was rarely reported (<1%).  
303 Most of the solicited AEs were self-limited in seven days, with a mean duration of less than  
304 three days. The occurrence of solicited systemic AEs after any dose of the study intervention  
305 in the ≥ 65 years age group (38.7%) was slightly lower than that in the overall Safety Set.  
306 Twenty-eight percent of participants (1,081/3,844) reported unsolicited AEs (Supplementary  
307 Table S6). The percentages of all participants who reported unsolicited AEs and other AEs in  
308 the overall Safety Set and by age group were comparable between the MVC-COV1901 and  
309 placebo groups.

310

311 None of the SAEs were related to the study intervention. One AESI was reported in one  
312 participant (< 0.1%) from the MVC-COV1901 group (temporary facial paralysis, possibly  
313 related). Neither death nor VAED were reported.

314

### 315 *Immunogenicity*

316 For the PPI Subset of the vaccinated group on D57, the SARS-CoV-2 wild type neutralising  
317 antibody GMT was 662.3 (95% CI [628.7, 697.7]), and the GMT ratio was 163.2 (95% CI  
318 [155.0, 171.9]), respectively. Both data were significantly higher ( $p < 0.0001$ ) than that of the  
319 placebo group (Figure 3 and Supplementary Table S7). In vaccinated group, the GMT was  
320 higher in the younger adult group 732.9 (95% CI [692.4, 775.7]) than the older adult group

321 484·5 (95% CI [433·2, 542·0]). The GMTs of NIBSC 20/136, 20/148, 20/144, and 20/140  
322 were 1,620, 258, 181, and 87, respectively. The GMTs of the neutralising antibody on Day 57  
323 for all participants in the PPI Subset, for the younger adult group, and for the older adult  
324 group when converted to WHO International Unit (IU) were: 408 IU/mL, 454 IU/mL, and  
325 296 IU/mL, respectively (Figure 3).

326

327 In the MVC-COV1901 group, the SCR on Day 57 based on the wild type SARS-CoV-2  
328 GMT was 99·8%, with only two participants failing to seroconvert. In the placebo group, no  
329 seroconversion was observed (Supplementary Table S8). In both age groups, almost all  
330 participants achieved seroconversion (99·9% in younger adults and 99·5% in older adults).

331

332 After the first dose (Day 29), the anti-Spike IgG GMT of the PPI Subset increased to 430·5  
333 (95% CI [398·7, 464·8]) in the MVC-COV1901 group, whereas it remained at the baseline  
334 level in the placebo group. The anti-Spike IgG titre continued to increase to 8,262·2 (95% CI  
335 [7,801·9, 8,749·5]) on Day 43 and remained as high as 5745·4 (95% CI [5,464·5, 6,040·6]) on  
336 Day 57 (Figure 4 and Supplementary Table S9). The younger adult group had higher  
337 anti-Spike IgG GMTs than those of older adult group. The GMTs for the younger adult group  
338 were 524 (95% CI [482·7, 569·4]) on Day 29, 9,638 (95% CI [9,070·7, 10,239·9]) on Day 43,  
339 and 6,521 (95% CI [6,188·3, 6,871·3]) on Day 57. The GMTs for the older adult group were  
340 233 (95% CI [198·9, 273·1]) on Day 29, 5,126 (95% CI [4,538·3, 5,789·2]) on Day 43, and  
341 3,887 (95% CI [3,476·1, 4,346·7]) on Day 57 (Supplementary Table S9). The anti-Spike IgG  
342 GMT on Day 57 for all the participants in the PPI Subset, for the younger adult group, for the  
343 older adult group when converted to WHO's Binding Antibody Unit (BAU/mL) were: 524  
344 BAU/mL, 595 BAU/mL, and 355 BAU/mL, respectively. Supplementary Table S10  
345 illustrates D57 neutralising and binding antibody GMTs converted to WHO's IU & BAU.

346

347 The SCR of anti-Spike IgG titre was 74·4% in all PPI Subset on Day 29, and it increased to  
348 99·7% on Day 43, and 99·6% on Day 57 (Supplementary Table S11). On Day 29, the SCR  
349 was 53·9% in the older adult group, and 80·9% in the younger adult group. However, the  
350 SCR for both age groups became comparable on Day 43 (99·5% vs. 99·7%).

351

## 352 Discussion

353 This phase 2 trial design followed the principle of the October 2020 US FDA guidance for  
354 industry on EUA for vaccines to prevent COVID-19.<sup>10</sup> By the time of this interim analysis,  
355 3,295 participants have received at least one dose of MVC-COV1901. The median follow-up  
356 has reached 63 days, and all study participants have received follow-ups for over a month.  
357 The number of participants in the vaccine group (>3,000) and the accumulated safety data  
358 published here meet the principles outlined by the US FDA guidance.

359

360 The antigen of MVC-COV1901 was designed by Dr. McLellan and Dr. Graham. This antigen  
361 design involves a range of molecular modifications of the S-2P prefusion spike protein,  
362 furitin cleavage site mutation, and T4 fibrin for trimerization.<sup>4</sup> The combination of CpG  
363 1018 and aluminium hydroxide with this S-2P prefusion spike protein shows promising  
364 enhancements of both T-cell and B-cell immunity, as demonstrated in our phase 1 trial.<sup>7</sup> The  
365 interim analysis of MVC-COV1901 shows that in participants aged 20 years and older,  
366 receiving two doses of vaccination is safe, well-tolerated, and reaches favourable levels of  
367 neutralising antibody immunogenicity. One of the most distinct findings in our safety profile  
368 is the extremely low incidence of fever: 0.3% for the vaccinated group and 0.2% for the  
369 placebo group. Compared to other vaccines that have received EUA,<sup>12-14</sup> MVC-COV1901  
370 causes significantly fewer febrile reactions and has good reactogenicity profile, as seen in this  
371 study and our phase 1 trial.<sup>7</sup>

372

373 This trial began in December 2020, when SARS-CoV-2 was not endemic in Taiwan.  
374 Therefore, very low levels of wildtype neutralising antibody GMTs were detected in all study  
375 participants at the baseline (4.06). However, on Day 57 whereas the GMT for the placebo  
376 group stayed at 4.0, the GMT for the MVC-COV1901 group spiked to 662.31, which is most  
377 likely the results of vaccination.

378

379 David Khoury et al. demonstrated that comparing neutralising antibody titres to human  
380 convalescent sera (HCS) can be used to predict clinical efficacy for vaccines across different  
381 technology platforms.<sup>15</sup> However, the neutralising antibody titres of convalescent sera vary  
382 significantly depending on the degree of disease severity and individual immune response.  
383 This variation makes back-to-back comparison of different HCS difficult, if not impossible.  
384 To facilitate comparison and avoid mis-extrapolation of the GMT titres on prediction of  
385 efficacy, we used two different sets of HCS as parameters to estimate the ratio of our  
386 neutralising antibody GMT against the GMT of HCS.

387

388 Our first parameter is based on Khoury's article, which reported that 20% of HCS (54 IU/mL)  
389 can approximate 50% vaccine efficacy. Therefore, when we set 270 IU/mL as the GMT of

390 HCS (54 IU/20% = 270 IU/mL), the GMT on Day 57 for the MVC-COV1901 group was  
391 1.51 times that of HCS. The second parameter was based on WHO's reference panel NIBSC  
392 20/148, which measured at 210 IU/mL in Figure 3. At 210 IU/mL as mid HCS, the GMT on  
393 Day 57 for MVC-COV1901 group is 1.94 times that of HCS. When compared to the HCS for  
394 both parameters, our neutralising antibody GMTs for all participants in the PPI Subset on  
395 Day 57 are approximately 1.51-1.94 times higher.

396

397 Another method to predict clinical efficacy is the Binding Antibody Unit (BAU) conversion  
398 model. Researchers of the University of Oxford<sup>16</sup> published the correlates of protection (CoP)  
399 for AstraZeneca COVID-19 vaccine against symptomatic and asymptomatic SARS-CoV-2  
400 infection, which is the only CoP published to date. When converted to WHO's BAU, the  
401 report showed that if the anti-Spike IgG level is between 264 and 899, the predicted vaccine  
402 efficacy is between 80% to 90%. In our study for MVC-COV1901, the anti-Spike IgG GMT  
403 on Day 57 for all PPI Subset was 524 BAU/mL; for the younger adult group was 595  
404 BAU/mL; for the older adult group was 355 BAU/mL. Even though the effects of cellular  
405 immunity and ethnic differences remain unclear, in both the IU and the BAU conversion  
406 models, MVC-COV1901 has yielded comparable vaccine efficacy predictions.

407

408 For regulatory authorities to use CoP for cross-vaccine comparison to predict clinical efficacy,  
409 a standardised assay which converts GMT to IU or BAU will be a pre-requisite.<sup>17,18</sup> This  
410 conversion assay would expedite vaccine approval, facilitate cross-checking of  
411 immunogenicity between trials, and enable data comparisons among different labs. This  
412 study is, to our knowledge, the first to report neutralising antibody titres and anti-Spike IgG  
413 titres using WHO's IU and BAU for a COVID-19 vaccine in phase 2. We applied the IU  
414 conversion methodology to validate the consistency of immunogenicity between our phase 1  
415 and phase 2 trials from different labs. Using WHO's IU, our phase 1 GMT on Day 57 was  
416 converted from 52.2 to 351.2 IU/mL, and our phase 2 GMT on Day 57 was converted from

417 663.2 to 408 IU/mL. The converted GMTs indicate that the immunogenicity data from our  
418 phase 1 and phase 2 trials is comparable. Our results demonstrate the many benefits of  
419 standardised assays which may facilitate the application of CoP for regulatory authorities to  
420 consider.

421

422 It is paramount for a COVID-19 vaccine to render protection for people at higher risk of  
423 severe complications. Several reports show that elderly patients with chronic comorbidities  
424 have higher mortality rates of COVID-19.<sup>19,20</sup> In this phase 2 trial, we included older adult  
425 participants with various chronic comorbidities in stable conditions, which allowed us to

426 assess the safety and immunogenicity profiles of MVC-COV1901 for this age group. Since  
427 the safety profiles, neutralising titres, tolerability, and vaccine-related SAEs are comparable  
428 between the younger adult and older adult groups, MVC-COV1901 is suitable for older  
429 adults over 65 years of age with comorbidities.

430

431 We acknowledge the limitations of our current study. The low viral transmission rate in  
432 Taiwan at the time of the study, coupled with the relatively small size of the placebo group,  
433 hindered observation of both vaccine efficacy as the exploratory endpoint and the risk of  
434 VAED. The short duration of the follow-up period before the interim analysis prevented us  
435 from assessing the durability of immune responses after Day 57; the long-term follow-up will  
436 be available upon completion of this phase 2 trial in October 2021. The racial diversity of  
437 study participants is restricted to ethnicities in Taiwan. These limitations will be addressed in  
438 our phase 3 trials, which will be conducted in regions outside Taiwan where COVID-19  
439 infection rates are high.

440

441 To conclude, this interim analysis shows that MVC-COV1901 has good safety profiles and  
442 promising neutralising antibody titres. MVC-COV1901 is safe, well-tolerated, and rarely  
443 causes febrile reactions in both young adults and older adults. MVC-COV1901 induces high  
444 neutralising antibody and anti-Spike IgG GMTs, and its seroconversion rate is nearly 100%  
445 on Day 57. Using WHO's IU and BAU conversion models, the predicted clinical efficacy for  
446 MVC-COV1901 is comparable for both methods. The phase 2 trial results support the  
447 advancement of MVC-COV1901 in subsequent phase 3 trials. MVC-COV1901 has recently  
448 been granted EUA in Taiwan.

449

#### 450 ***Author contributions***

451 Hsieh SM, Lin TY, Lien CE and Tai IC had full access to all the data in this study and take  
452 responsibility for the integrity of the data and the accuracy of the data analysis. Lin TY and  
453 Tai IC contributed equally and are joint corresponding authors.

454 Concept and design: Hsieh SM and Tai IC.

455 Acquisition or interpretation of data: Hsieh SM, Liu MC, Chen YS, Lee WS, Hwang SJ,  
456 Cheng SH, Hwang KP, Ko WC, Wang NC, and Lee YL.

457 Drafting and preparation of the manuscript: Hsieh SM, Liu Mc, Chen YS, Lee WS, Hwang SJ,  
458 Cheng SH, Lien CE, Tai IC and Lin TY.

459 Laboratory assays set up, assay conduction, and data analysis: Lin YL, Huang CG, Shih SR,  
460 Liao CC, Liang JJ, Chang CS.

461 Administrative, technical, and material support: Chen C.

462 All authors reviewed and approved the final version of the manuscript.

463

464 ***Declaration of interests***

465 Hsieh SM, Liu Mc, Chen YS, Lee WS, Hwang SJ, Cheng SH, Ko WC, Hwang KP, Wang NC,  
466 Lee YL, Lin YL, Shih SR, Huang CG, Liao CC, Liang JJ, Chang CS, and Lin TY declared  
467 that they have no known competing financial interests or personal relationships that could  
468 influence the work reported in this paper; Chen C, Lien CE, and Tai IC are employees of  
469 Medigen Vaccine Biologics Corporation and reported grants from Taiwan Centres for Disease  
470 Control, Ministry of Health and Welfare, during the conduct of the study. In addition, Chen C  
471 has a patent US17/351,363 pending.

472

473 ***Acknowledgements***

474 The authors would like to thank:

475 Dr. Stanley Chang, Dr. Meei-Yun Lin, and Dr. Luke Tzu-Chi Liu at Medigen Vaccine  
476 Biologics Corp. for manuscript drafting, editing, and revision.

477 All the participants for their dedication to this trial.

478 The investigational staff at National Taiwan University Hospital, Taiwan Taipei Veterans  
479 General Hospital, Tri-Service General Hospital, Taipei Veterans General Hospital, Taipei  
480 Medical University Hospital, Taipei Municipal Wan Fang Hospital, Linkou Chang Gung  
481 Medical Hospital, Tao-Yuan General Hospital, China Medical University Hospital, Changhua  
482 Christian Hospital, National Cheng Kung University Hospital, and Kaohsiung Medical  
483 University Chung-Ho Memorial Hospital, Clinipace Clinical Research Team, Taiwan., and  
484 Hao-Yuan Cheng, Criss Cheng, Meng-Ju Tsai at Medigen Vaccine Biologics Corp. for the  
485 conduction of the trial.

486 Dr. Barney S. Graham, at Vaccine Research Centre, National Institute of Allergy and  
487 Infectious Diseases, U.S.A. for the development of S-2P prefusion protein.

488 Dr. Tsun-Yung Kuo and team at Department of Biotechnology and Animal Science, National  
489 Ilan University, Ilan, Taiwan for technical guidance and scientific advice.

490 Dr. Robert Janssen at Dynavax Technologies for providing critical intellectual content of the  
491 manuscript.

492 Dynavax Technologies for providing the CpG 1018 adjuvant.

493 Dr. Wei-Cheng Lian, Dr. Erh-Fang Hsieh, Dr. Yi-Jiun Li at Medigen Vaccine Biologics Corp.  
494 for collaboration on vaccine production, significant contribution to the Investigational New  
495 Drug (IND) application, and laboratory assay development.

496 The members of the Independent Data Monitoring Committee.

497 Team members at Protech Pharmaservices Corp. for spike specific IgG ELISA assay.

498 Team members at the Department of Laboratory Medicine, Linkou Chang Gung Memorial  
499 Hospital, and Institute of Biomedical Sciences, Academia Sinica for neutralisation assay  
500 conduction.

501

## 502 **References**

- 503 1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new  
504 coronavirus of probable bat origin. *Nature*. 2020, 579(7798):270-273.
- 505 2. World Health Organization. WHO Director-General's opening remarks at the mission  
506 briefing on COVID-19—11 March 2020. World Health Organization. March 11, 2020.  
507 Available at: [\\_](#) Accessed June 5, 2021.
- 508 3. Dong E, Du 1 & Gardner L. COVID-19 Dashboard by the Centre for Systems Science  
509 and Engineering (CSSE) at Johns Hopkins University (JHU). Available at:  
510 <https://coronavirus.jhu.edu/map.html>. Accessed June 8, 2021.
- 511 4. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the  
512 prefusion conformation. *Science* 2020; **367**: 1260–3.
- 513 5. Kuo TY, Lin MY, Coffman RL, et al. Development of CpG-adjuvanted stable prefusion  
514 SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. *Sci Rep*, 2020;  
515 10:20085.
- 516 6. Lien CE, Lin YJ, Kuo TY, et al. CpG-adjuvanted stable prefusion SARS-CoV-2 spike  
517 protein protected hamsters from SARS-CoV-2 challenge. *Sci Rep*. 2021. 11(1):1-7.
- 518 7. Hsieh SM, Liu WD, Huang YS et al. Safety and Immunogenicity of a Recombinant  
519 Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted  
520 With CpG 1018 and Aluminium Hydroxide in Healthy Adults: A Phase 1,  
521 Dose-Escalation Study. *EClinicalMedicine*. June 26, 2021. Available from:  
522 <https://doi.org/10.1016/j.eclinm.2021.100989>.
- 523 8. National Institute for Biological Standards and Control (NIBSC). WHO International  
524 Standard First WHO International Standard for anti-SARS-CoV-2 immunoglobulin  
525 (human), NIBSC code: 20/136, Instructions for use, version 2.0. December 17, 2020.
- 526 9. National Institute for Biological Standards and Control (NIBSC). WHO Reference Panel  
527 First WHO International Reference Panel for anti-SARS-CoV-2 immunoglobulin, NIBSC  
528 code: 20/268, Instructions for use, version 3.0. December 17, 2020.
- 529 10. U.S. Food and Drug Administration (FDA). Emergency Use Authorization for Vaccines to  
530 Prevent COVID-19. Guidance for Industry. October, 2020. Available at:  
531 [https://downloads.regulations.gov/FDA-2020-D-1137-0019/attachment\\_1.pdf](https://downloads.regulations.gov/FDA-2020-D-1137-0019/attachment_1.pdf) Accessed  
532 July 19, 2021.
- 533 11. WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations. 21 October  
534 2020 Meeting report: 566-7. Available at  
535 <https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9>. Accessed July  
536 17, 2021.
- 537 12. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D,  
538 Bibi S, Bittaye M, Clutterbuck EA, Dold C. Safety and immunogenicity of the ChAdOx1  
539 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind,

- 540 randomised controlled trial. *The Lancet*. 2020 Aug 15; 396(10249):467-78.
- 541 13. Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, Leav B, mRNA-1273  
542 Study Group. A preliminary report of a randomized controlled phase 2 trial of the safety  
543 and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. *Vaccine*. 2021 May 12;  
544 39(20):2791-9.
- 545 14. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V,  
546 Bailey R, Swanson KA, Li P. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in  
547 adults. *Nature*. 2020 Oct; 586(7830):589-93.
- 548 15. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K,  
549 Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of  
550 immune protection from symptomatic SARS-CoV-2 infection. *Nature medicine*. 2021  
551 May 17:1-7.
- 552 16. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection  
553 against symptomatic and asymptomatic SARS-CoV-2 infection. *medRxiv*. 2021 Jan 1.  
554 DOI: <https://doi.org/10.1101/2021.06.21.21258528>
- 555 17. Cohen J. Can immune responses predict which vaccines work best? *Science*. 2021 Jul  
556 09;373(6551):142-143
- 557 18. Corey L, Mascola JR, Fauci AS, Collins FS, et al. A Strategic approach to COVID-19  
558 vaccine R&D. *Science*. 29 May 2020:Vol. 368, Issue 6494, pp. 948-950. DOI:  
559 10.1126/science.abc5312
- 560 19. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, Bonanomi E,  
561 Cabrini L, Carlesso E, Castelli G, Cattaneo S . Risk factors associated with mortality  
562 among patients with COVID-19 in intensive care units in Lombardy, Italy. *JAMA internal*  
563 *medicine*. 2020 Oct 1; 180(10):1345-55.
- 564 20. Noor FM, Islam MM. Prevalence and associated risk factors of mortality among  
565 COVID-19 patients: a meta-analysis. *Journal of community health*. 2020 Dec;  
566 45(6):1270-82.



567 **Figure Legends**

568 **Figure 1. Consort Flow Diagram of the study**

569

570 **Figure 2. Solicited (A) Local and (B) Systemic Adverse Events within 7 days of first or**  
571 **second dose of study intervention**

572 Severity gradings are as follows: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe

573


574 **Figure 3. Neutralising antibody titres against live wild type SARS-CoV-2 virus on Day 1**  
575 **and Day 57**

576 The height of the bar represents GMT, and the error bars represent 95% CI of the GMT. GMT  
577 values are marked above the bars that have values over LoD ( $> 8$ ). The mean value of the  
578 triplicated measurement of each NIBSC standard is indicated above or below a dot, and the  
579 name of the standard is indicated on the side of the axis. The values in IU/mL are in  
580 parentheses.

581

582 **Figure 4. Anti-Spike IgG GMTs measured by ELISA using S-2P as coated antigen on**  
583 **Day 1, Day 29, Day 43, and Day 57.**

584 The height of the bar represents GMT, and the error bars represent 95% CI of the GMT. GMT  
585 values are marked above the bars that have values above LoD ( $> 100$ ). The values in  
586 BAU/mL are in parentheses.



Screened  
N=4173

Excluded  
N=319

Randomised  
N=3854

Assigned to MVC-COV1901  
N=3304

Assigned to placebo  
N=550

Study intervention discontinuation	N=33
Pathological event or clinical AE	N=1
Investigator's decision due to any change in the participant's condition	N=1
Contraindication to study intervention	N=5
Withdrawal of consent	N=11
Pregnancy	N=4
Lost to follow up	N=6
Others	N=5

Received at least one dose of MVC-COV1901 (Safety Set)  
N=3295  
Received only one dose of MVC-COV1901  
N=24



Received at least one dose of placebo (Safety Set)  
N=549  
Received only one dose of placebo  
N=4

Study intervention discontinuation	N=5
Pathological event or clinical AE	N=1
Withdrawal of consent	N=3
Others	N=1


Received two doses of MVC-COV1901  
N=3271

Received two doses of placebo  
N=545


## A. Solicited Local Adverse Events





## B. Solicited Systemic Adverse Events



medRxiv preprint doi: <https://doi.org/10.1101/2021.08.05.21261632>; this version posted August 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.







medRxiv preprint doi: <https://doi.org/10.1101/2021.08.05.21261532>; this version posted August 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.